



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

31 July 2014  
EMA/477726/2014  
Human Medicines Development and Evaluation

## Public statement on Ioa

### Withdrawal of the marketing authorisation in the European Union

On 16 November 2011, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Ioa, which had been approved for oral contraception.

The marketing authorisation holder (MAH) responsible for Ioa was Merck Sharp & Dohme Limited.

On 31 July 2014, the European Commission issued a decision to withdraw the marketing authorisation for Ioa, following its receipt of a letter dated 18 June 2014 notifying the Commission of the MAH's decision to voluntarily withdraw the marketing authorisation for this product for commercial reasons.

Ioa was not marketed in any European country.

Pursuant to this decision, the European public assessment report for Ioa will be updated to reflect that the marketing authorisation is no longer valid.

